News | April 01, 2022
Sumitomo Chemical to build new API and intermediates plant in Japan
The plant is scheduled to come on stream in September 2024
The plant is scheduled to come on stream in September 2024
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
